Sustained API pricing pressure
API business continues to face pricing softness across key molecules, though the pace of decline has moderated.
high · management_commentaryAkums Drugs & Pharmaceuticals Ltd — Q3 FY26
Akums delivered a strong Q3 FY26 with operating revenue of ₹1,160 crore (+14.8% YoY) and EBITDA of ₹147 crore (+21% YoY), driven by 16% volume growth in CDMO and recovery in int...
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Potential delays in regulatory approvals for new facilities
The injectables facility is still ramping up with low utilization; delays in client audits or approvals could impact revenue contribution.
medium · analyst_questionTrade generic segment losses may persist
Trade generic revenue declined 18% YoY and remains loss-making; management expects some bottom-line impact in Q4.
medium · management_commentaryDependence on CDMO volume growth sustainability
Analyst questioned whether the strong volume growth is sustainable; management cited market share gains but acknowledged it's market-driven.
medium · analyst_question